Virtu Financial LLC Takes $83,000 Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Virtu Financial LLC purchased a new position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 15,694 shares of the company’s stock, valued at approximately $83,000.

Other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in shares of Corvus Pharmaceuticals by 22.4% in the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock valued at $2,974,000 after buying an additional 102,869 shares during the last quarter. XTX Topco Ltd bought a new stake in Corvus Pharmaceuticals in the 3rd quarter valued at $74,000. Jane Street Group LLC acquired a new stake in Corvus Pharmaceuticals during the 3rd quarter valued at $265,000. State Street Corp boosted its position in Corvus Pharmaceuticals by 48.2% during the third quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after purchasing an additional 57,943 shares during the period. Finally, Nwam LLC acquired a new position in shares of Corvus Pharmaceuticals in the third quarter valued at $53,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Wall Street Analysts Forecast Growth

CRVS has been the subject of a number of research reports. Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. LADENBURG THALM/SH SH raised their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Oppenheimer upped their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.83.

Corvus Pharmaceuticals Stock Up 8.3 %

NASDAQ CRVS opened at $5.09 on Friday. The firm has a 50-day moving average price of $8.14 and a two-hundred day moving average price of $5.05. Corvus Pharmaceuticals, Inc. has a 12-month low of $1.30 and a 12-month high of $10.00. The company has a market capitalization of $327.07 million, a P/E ratio of -5.47 and a beta of 1.05.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.